Free Trial

Treace Medical Concepts (TMCI) Financials

Treace Medical Concepts logo
$5.90 +0.06 (+0.94%)
As of 10:23 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Treace Medical Concepts

Annual Income Statements for Treace Medical Concepts

This table shows Treace Medical Concepts' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-56 -49 -43
Consolidated Net Income / (Loss)
-56 -50 -43
Net Income / (Loss) Continuing Operations
-56 -50 -43
Total Pre-Tax Income
-56 -50 -43
Total Operating Income
-56 -51 -35
Total Gross Profit
168 152 116
Total Revenue
209 187 142
Operating Revenue
209 187 142
Total Cost of Revenue
41 35 26
Operating Cost of Revenue
41 35 26
Total Operating Expenses
224 203 151
Selling, General & Admin Expense
56 47 33
Marketing Expense
148 141 105
Research & Development Expense
21 15 14
Other Operating Expenses / (Income)
-0.32 -0.34 -
Total Other Income / (Expense), net
-0.50 1.90 -7.97
Interest Expense
5.26 5.17 8.88
Interest & Investment Income
4.88 6.73 1.31
Other Income / (Expense), net
-0.12 - -0.40
Basic Earnings per Share
($0.90) ($0.81) ($0.77)
Weighted Average Basic Shares Outstanding
62.11M 60.85M 55.28M
Diluted Earnings per Share
($0.90) ($0.81) ($0.77)
Weighted Average Diluted Shares Outstanding
62.11M 60.85M 55.28M
Weighted Average Basic & Diluted Shares Outstanding
62.62M 61.76M 61.16M

Quarterly Income Statements for Treace Medical Concepts

This table shows Treace Medical Concepts' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-0.50 -15 -21 -19 -5.97 -17 -12 -13 -8.11 -12
Consolidated Net Income / (Loss)
-0.50 -15 -21 -19 -6.28 -18 -12 -13 -4.41 -12
Net Income / (Loss) Continuing Operations
-1.01 -15 -21 -19 -6.51 -18 -12 -13 -8.13 -12
Total Pre-Tax Income
-1.01 -15 -21 -19 -6.51 -18 -12 -13 -8.13 -12
Total Operating Income
-0.20 -15 -21 -19 -6.78 -18 -13 -14 -3.50 -11
Total Gross Profit
55 36 36 41 51 33 34 34 41 27
Total Revenue
69 45 44 51 62 41 42 42 50 33
Operating Revenue
69 45 44 51 62 41 42 42 50 33
Total Cost of Revenue
13 8.95 8.78 10 11 8.00 7.68 8.04 9.02 6.09
Operating Cost of Revenue
13 8.95 8.78 10 11 8.00 7.68 8.04 9.02 6.09
Total Operating Expenses
56 51 57 60 57 51 47 48 44 38
Selling, General & Admin Expense
14 14 14 14 13 13 10 11 10 8.92
Marketing Expense
37 33 38 40 40 34 34 34 30 26
Research & Development Expense
5.21 4.96 5.16 5.26 4.15 4.35 3.53 3.41 3.75 3.80
Other Operating Expenses / (Income)
-0.12 -0.02 -0.11 -0.07 - -0.02 -0.10 - - 0.05
Total Other Income / (Expense), net
-0.81 -0.26 0.15 0.42 0.50 0.30 0.78 0.32 -4.58 -0.82
Interest Expense
1.31 1.31 1.31 1.32 1.30 1.30 1.28 1.29 10 1.19
Interest & Investment Income
0.90 1.07 1.38 1.54 1.71 1.57 1.97 1.48 0.75 0.42
Other Income / (Expense), net
-0.39 -0.01 0.08 0.20 - - - 0.13 - -
Basic Earnings per Share
($0.01) ($0.25) ($0.34) ($0.30) ($0.10) ($0.28) ($0.20) ($0.23) ($0.08) ($0.22)
Weighted Average Basic Shares Outstanding
62.11M 62.23M 62.08M 61.79M 60.85M 61.56M 61.38M 58.72M 55.28M 55.43M
Diluted Earnings per Share
($0.01) ($0.25) ($0.34) ($0.30) ($0.10) ($0.28) ($0.20) ($0.23) ($0.08) ($0.22)
Weighted Average Diluted Shares Outstanding
62.11M 62.23M 62.08M 61.79M 60.85M 61.56M 61.38M 58.72M 55.28M 55.43M
Weighted Average Basic & Diluted Shares Outstanding
62.62M 62.30M 62.19M 62.01M 61.76M 61.68M 61.54M 61.33M 61.16M 55.50M

Annual Cash Flow Statements for Treace Medical Concepts

This table details how cash moves in and out of Treace Medical Concepts' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
-1.63 -6.49 -86
Net Cash From Operating Activities
-37 -35 -31
Net Cash From Continuing Operating Activities
-37 -35 -31
Net Income / (Loss) Continuing Operations
-56 -50 -43
Consolidated Net Income / (Loss)
-56 -50 -43
Depreciation Expense
8.42 5.35 2.13
Amortization Expense
-0.85 -1.11 0.12
Non-Cash Adjustments To Reconcile Net Income
34 20 16
Changes in Operating Assets and Liabilities, net
-23 -9.74 -5.81
Net Cash From Investing Activities
35 -81 -77
Net Cash From Continuing Investing Activities
35 -81 -77
Purchase of Property, Plant & Equipment
-12 -11 -15
Acquisitions
0.00 -20 0.00
Purchase of Investments
-72 -170 -63
Sale and/or Maturity of Investments
119 120 1.73
Net Cash From Financing Activities
0.16 109 21
Net Cash From Continuing Financing Activities
0.16 109 21
Repayment of Debt
0.00 0.00 -0.99
Issuance of Debt
0.00 0.00 50
Issuance of Common Equity
0.00 108 0.00
Other Financing Activities, net
0.16 1.86 -28
Cash Interest Paid
4.96 5.17 4.40

Quarterly Cash Flow Statements for Treace Medical Concepts

This table details how cash moves in and out of Treace Medical Concepts' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-0.76 -6.07 8.85 -3.65 5.70 -4.76 -18 10 -69 -4.29
Net Cash From Operating Activities
-4.21 -12 -14 -7.22 0.53 -9.51 -8.34 -17 -5.36 -7.48
Net Cash From Continuing Operating Activities
-4.21 -12 -14 -7.22 0.53 -9.51 -8.47 -17 -5.65 1.51
Net Income / (Loss) Continuing Operations
-0.50 -15 -21 -19 -6.28 -18 -12 -13 -4.41 -12
Consolidated Net Income / (Loss)
-0.50 -15 -21 -19 -6.28 -18 -12 -13 -4.41 -12
Depreciation Expense
2.24 2.16 2.12 1.91 1.77 1.56 1.10 0.92 0.92 0.46
Amortization Expense
-0.15 -0.16 -0.28 -0.26 -0.30 -0.29 -0.29 -0.22 -0.05 0.07
Non-Cash Adjustments To Reconcile Net Income
8.75 8.81 8.16 8.25 6.86 4.88 4.66 4.04 3.98 12
Changes in Operating Assets and Liabilities, net
-15 -7.29 -2.69 1.56 -1.52 1.85 -1.67 -8.41 -6.09 1.00
Net Cash From Investing Activities
3.42 5.76 22 3.76 5.01 4.60 -10 -80 -64 -5.86
Net Cash From Continuing Investing Activities
3.42 5.76 22 3.76 5.01 4.60 -10 -80 -64 -5.86
Purchase of Property, Plant & Equipment
-3.07 -2.86 -1.73 -3.93 -2.25 -3.50 -4.23 -1.48 -2.33 -5.86
Purchase of Investments
-19 -24 - -29 -30 -19 -21 -100 -63 -
Sale and/or Maturity of Investments
25 33 24 36 37 27 35 21 1.73 -
Net Cash From Financing Activities
0.03 0.01 0.31 -0.19 0.17 0.16 1.18 108 0.30 0.35
Net Cash From Continuing Financing Activities
0.03 0.01 0.31 -0.19 0.17 0.16 1.18 108 0.30 0.35
Other Financing Activities, net
0.03 0.01 0.31 -0.19 0.17 0.16 1.18 0.35 -34 0.35
Cash Interest Paid
1.22 1.24 1.17 1.32 1.30 1.30 1.28 1.29 1.31 1.19

Annual Balance Sheets for Treace Medical Concepts

This table presents Treace Medical Concepts' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
217 252 159
Total Current Assets
161 198 133
Cash & Equivalents
11 13 19
Short-Term Investments
64 110 62
Accounts Receivable
41 38 29
Inventories, net
39 29 19
Prepaid Expenses
5.67 7.85 3.62
Plant, Property, & Equipment, net
26 22 15
Total Noncurrent Assets
30 31 10
Goodwill
13 13 0.00
Intangible Assets
8.08 9.03 0.00
Other Noncurrent Operating Assets
8.85 9.41 10
Total Liabilities & Shareholders' Equity
217 252 159
Total Liabilities
104 114 98
Total Current Liabilities
35 45 30
Accounts Payable
11 12 8.67
Accrued Expenses
17 21 14
Current Employee Benefit Liabilities
6.58 7.55 7.67
Other Current Liabilities
0.51 4.43 0.34
Total Noncurrent Liabilities
69 69 68
Long-Term Debt
53 53 53
Other Noncurrent Operating Liabilities
16 16 16
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
113 138 61
Total Preferred & Common Equity
113 138 61
Preferred Stock
0.00 0.00 0.00
Total Common Equity
113 138 61
Common Stock
303 272 145
Retained Earnings
-190 -134 -85
Treasury Stock
-0.28 -0.01 0.00
Accumulated Other Comprehensive Income / (Loss)
0.10 0.16 -0.03

Quarterly Balance Sheets for Treace Medical Concepts

This table presents Treace Medical Concepts' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
213 226 243 240 250 249 156
Total Current Assets
158 172 187 187 198 223 128
Cash & Equivalents
12 18 9.33 7.28 12 30 89
Short-Term Investments
71 77 101 115 127 141 -
Accounts Receivable
24 26 30 25 27 25 19
Inventories, net
44 41 36 29 26 23 17
Prepaid Expenses
7.02 9.67 11 11 5.28 4.59 4.01
Plant, Property, & Equipment, net
25 24 25 22 19 16 14
Total Noncurrent Assets
30 30 31 32 32 10 14
Goodwill
13 13 13 13 13 - -
Intangible Assets
8.31 8.55 8.79 9.26 9.50 - -
Other Noncurrent Operating Assets
9.03 8.92 9.21 9.61 9.80 10 14
Total Liabilities & Shareholders' Equity
213 226 243 240 250 249 156
Total Liabilities
108 114 116 103 100 92 94
Total Current Liabilities
38 44 47 33 30 23 23
Accounts Payable
19 18 21 8.68 8.15 5.08 7.88
Accrued Expenses
13 20 21 14 13 14 9.32
Current Employee Benefit Liabilities
5.60 6.19 4.20 5.07 5.37 3.30 5.05
Other Current Liabilities
0.57 0.52 1.02 5.19 3.78 - 0.33
Total Noncurrent Liabilities
70 69 69 69 70 68 72
Long-Term Debt
53 53 53 53 53 53 53
Other Noncurrent Operating Liabilities
17 16 16 16 17 15 19
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
105 112 126 138 150 158 62
Total Preferred & Common Equity
105 112 126 138 150 158 62
Preferred Stock
0.00 0.00 0.00 0.00 - - 0.00
Total Common Equity
105 112 126 138 150 158 62
Common Stock
294 287 279 266 261 256 143
Retained Earnings
-189 -174 -153 -128 -110 -98 -80
Treasury Stock
-0.25 -0.25 -0.25 - - - -
Accumulated Other Comprehensive Income / (Loss)
0.19 -0.03 0.07 -0.15 -0.22 -0.06 -

Annual Metrics And Ratios for Treace Medical Concepts

This table displays calculated financial ratios and metrics derived from Treace Medical Concepts' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
11.89% 31.92% 50.22%
EBITDA Growth
-2.23% -43.00% -110.85%
EBIT Growth
-8.52% -45.91% -113.49%
NOPAT Growth
-8.28% -47.60% -111.05%
Net Income Growth
-12.55% -15.68% -108.33%
EPS Growth
-11.11% -5.19% -79.07%
Operating Cash Flow Growth
-7.50% -12.81% -78.26%
Free Cash Flow Firm Growth
13.94% -80.42% -174.53%
Invested Capital Growth
33.61% 111.79% 92.64%
Revenue Q/Q Growth
3.20% 7.12% 13.01%
EBITDA Q/Q Growth
12.79% -6.03% 6.37%
EBIT Q/Q Growth
10.37% -6.82% 4.59%
NOPAT Q/Q Growth
10.56% -6.82% 5.68%
Net Income Q/Q Growth
9.39% -3.92% 4.90%
EPS Q/Q Growth
9.09% -2.53% 7.23%
Operating Cash Flow Q/Q Growth
-14.61% 14.56% -5.53%
Free Cash Flow Firm Q/Q Growth
-22.79% 5.63% -13.91%
Invested Capital Q/Q Growth
20.15% -1.29% 21.67%
Profitability Metrics
- - -
Gross Margin
80.37% 81.20% 82.00%
EBITDA Margin
-23.04% -25.22% -23.26%
Operating Margin
-26.60% -27.48% -24.57%
EBIT Margin
-26.66% -27.48% -24.85%
Profit (Net Income) Margin
-26.63% -26.47% -30.19%
Tax Burden Percent
99.21% 99.31% 100.00%
Interest Burden Percent
100.68% 96.97% 121.47%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-49.26% -72.19% -100.39%
ROIC Less NNEP Spread (ROIC-NNEP)
-13.04% -44.79% -65.30%
Return on Net Nonoperating Assets (RNNOA)
4.81% 22.28% 44.64%
Return on Equity (ROE)
-44.45% -49.91% -55.75%
Cash Return on Invested Capital (CROIC)
-78.04% -143.90% -163.70%
Operating Return on Assets (OROA)
-23.80% -25.03% -23.51%
Return on Assets (ROA)
-23.77% -24.10% -28.56%
Return on Common Equity (ROCE)
-44.45% -49.91% -55.73%
Return on Equity Simple (ROE_SIMPLE)
-49.38% -35.91% -70.73%
Net Operating Profit after Tax (NOPAT)
-39 -36 -24
NOPAT Margin
-18.62% -19.24% -17.20%
Net Nonoperating Expense Percent (NNEP)
-36.22% -27.40% -35.09%
Return On Investment Capital (ROIC_SIMPLE)
-23.45% -18.85% -21.54%
Cost of Revenue to Revenue
19.63% 18.80% 18.00%
SG&A Expenses to Revenue
26.61% 25.13% 23.27%
R&D to Revenue
9.83% 8.25% 9.58%
Operating Expenses to Revenue
106.82% 108.50% 106.57%
Earnings before Interest and Taxes (EBIT)
-56 -51 -35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-48 -47 -33
Valuation Ratios
- - -
Price to Book Value (P/BV)
4.11 5.70 21.08
Price to Tangible Book Value (P/TBV)
5.04 6.77 21.08
Price to Revenue (P/Rev)
2.21 4.20 9.00
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
4.87 10.57 39.00
Enterprise Value to Revenue (EV/Rev)
2.11 3.83 8.79
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.47 0.38 0.87
Long-Term Debt to Equity
0.47 0.38 0.87
Financial Leverage
-0.37 -0.50 -0.68
Leverage Ratio
1.87 2.07 1.95
Compound Leverage Factor
1.88 2.01 2.37
Debt to Total Capital
32.07% 27.76% 46.55%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
32.07% 27.76% 46.55%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
67.93% 72.24% 53.45%
Debt to EBITDA
-1.11 -1.12 -1.60
Net Debt to EBITDA
0.46 1.49 0.87
Long-Term Debt to EBITDA
-1.11 -1.12 -1.60
Debt to NOPAT
-1.37 -1.47 -2.16
Net Debt to NOPAT
0.57 1.95 1.17
Long-Term Debt to NOPAT
-1.37 -1.47 -2.16
Altman Z-Score
2.26 4.19 7.97
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.03%
Liquidity Ratios
- - -
Current Ratio
4.62 4.40 4.41
Quick Ratio
3.34 3.58 3.65
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-62 -72 -40
Operating Cash Flow to CapEx
-320.60% -301.75% -206.55%
Free Cash Flow to Firm to Interest Expense
-11.75 -13.89 -4.48
Operating Cash Flow to Interest Expense
-7.07 -6.69 -3.45
Operating Cash Flow Less CapEx to Interest Expense
-9.28 -8.91 -5.12
Efficiency Ratios
- - -
Asset Turnover
0.89 0.91 0.95
Accounts Receivable Turnover
5.31 5.56 5.94
Inventory Turnover
1.20 1.45 1.71
Fixed Asset Turnover
8.68 9.94 15.60
Accounts Payable Turnover
3.68 3.43 4.01
Days Sales Outstanding (DSO)
68.75 65.60 61.46
Days Inventory Outstanding (DIO)
304.22 251.98 213.66
Days Payable Outstanding (DPO)
99.29 106.36 90.95
Cash Conversion Cycle (CCC)
273.68 211.22 184.16
Capital & Investment Metrics
- - -
Invested Capital
91 68 32
Invested Capital Turnover
2.65 3.75 5.84
Increase / (Decrease) in Invested Capital
23 36 15
Enterprise Value (EV)
441 716 1,247
Market Capitalization
463 786 1,276
Book Value per Share
$1.81 $2.24 $1.09
Tangible Book Value per Share
$1.48 $1.88 $1.09
Total Capital
166 191 113
Total Debt
53 53 53
Total Long-Term Debt
53 53 53
Net Debt
-22 -70 -29
Capital Expenditures (CapEx)
12 11 15
Debt-free, Cash-free Net Working Capital (DFCFNWC)
51 30 22
Debt-free Net Working Capital (DFNWC)
126 153 103
Net Working Capital (NWC)
126 153 103
Net Nonoperating Expense (NNE)
17 14 18
Net Nonoperating Obligations (NNO)
-22 -70 -29
Total Depreciation and Amortization (D&A)
7.57 4.24 2.25
Debt-free, Cash-free Net Working Capital to Revenue
24.26% 16.10% 15.44%
Debt-free Net Working Capital to Revenue
60.41% 81.94% 72.73%
Net Working Capital to Revenue
60.41% 81.94% 72.73%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($0.90) ($0.81) ($0.77)
Adjusted Weighted Average Basic Shares Outstanding
62.11M 60.85M 55.28M
Adjusted Diluted Earnings per Share
($0.90) ($0.81) ($0.77)
Adjusted Weighted Average Diluted Shares Outstanding
62.11M 60.85M 55.28M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
62.62M 61.76M 61.16M
Normalized Net Operating Profit after Tax (NOPAT)
-39 -36 -24
Normalized NOPAT Margin
-18.62% -19.24% -17.20%
Pre Tax Income Margin
-26.84% -26.65% -30.19%
Debt Service Ratios
- - -
EBIT to Interest Expense
-10.62 -9.95 -3.97
NOPAT to Interest Expense
-7.42 -6.97 -2.75
EBIT Less CapEx to Interest Expense
-12.82 -12.17 -5.64
NOPAT Less CapEx to Interest Expense
-9.62 -9.18 -4.42
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Treace Medical Concepts

This table displays calculated financial ratios and metrics derived from Treace Medical Concepts' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
10.44% 10.62% 5.96% 21.12% 25.00% 23.30% 40.00% 45.26% 48.84% 52.90%
EBITDA Growth
128.04% 20.56% -58.88% -32.24% -101.98% -53.43% 26.92% -67.77% 50.15% -106.37%
EBIT Growth
91.23% 15.01% -63.20% -37.53% -93.94% -57.43% 24.27% -68.58% 37.52% -107.29%
NOPAT Growth
96.99% 15.06% -63.82% -37.69% -93.94% -57.43% -9.38% -70.16% 37.52% -107.29%
Net Income Growth
92.02% 12.33% -72.81% -38.81% -42.36% -44.41% 28.80% -48.89% 33.34% -89.05%
EPS Growth
90.00% 10.71% -70.00% -30.43% -25.00% -27.27% 35.48% -43.75% 42.86% -83.33%
Operating Cash Flow Growth
-890.79% -24.48% -66.73% 58.16% 109.93% -27.13% 21.11% -138.35% -42.80% 19.23%
Free Cash Flow Firm Growth
43.43% 68.44% 56.01% -28.30% -127.18% -222.83% -168.44% -195.06% -160.35% 19.37%
Invested Capital Growth
33.61% 9.77% 10.91% 70.27% 111.79% 161.04% 178.52% 129.91% 92.64% 52.54%
Revenue Q/Q Growth
52.39% 1.42% -13.02% -17.85% 52.64% -2.85% -0.57% -15.22% 50.56% 10.30%
EBITDA Q/Q Growth
111.34% 32.45% -13.67% -222.19% 67.89% -35.09% 5.39% -392.09% 75.61% 35.65%
EBIT Q/Q Growth
96.07% 28.91% -13.48% -176.76% 61.94% -36.52% 4.37% -290.28% 69.10% 34.33%
NOPAT Q/Q Growth
98.65% 29.22% -12.73% -179.68% 61.94% -36.52% 5.26% -293.94% 69.10% 5.15%
Net Income Q/Q Growth
96.74% 27.57% -13.55% -197.34% 64.15% -42.78% 8.79% -204.94% 63.64% 29.60%
EPS Q/Q Growth
96.00% 26.47% -13.33% -200.00% 64.29% -40.00% 13.04% -187.50% 63.64% 29.03%
Operating Cash Flow Q/Q Growth
64.47% 14.79% -92.45% -1,457.33% 105.59% -14.13% 51.71% -222.12% 28.40% 29.18%
Free Cash Flow Firm Q/Q Growth
-32.46% 20.93% 47.84% -3.56% 26.10% -10.21% -52.11% -83.37% -5.02% 8.36%
Invested Capital Q/Q Growth
20.15% 7.24% 1.13% 2.54% -1.29% 8.36% 55.25% 27.54% 21.67% 15.61%
Profitability Metrics
- - - - - - - - - -
Gross Margin
80.74% 80.14% 80.25% 80.19% 81.56% 80.38% 81.71% 80.95% 81.87% 81.58%
EBITDA Margin
2.17% -29.16% -43.78% -33.50% -8.54% -40.60% -29.20% -30.68% -5.29% -32.63%
Operating Margin
-0.30% -33.57% -48.10% -37.11% -10.90% -43.72% -31.11% -32.65% -7.03% -34.24%
EBIT Margin
-0.87% -33.59% -47.92% -36.73% -10.90% -43.72% -31.11% -32.35% -7.03% -34.24%
Profit (Net Income) Margin
-0.73% -34.07% -47.70% -36.54% -10.10% -42.99% -29.25% -31.89% -8.87% -36.71%
Tax Burden Percent
49.60% 99.81% 99.85% 100.67% 96.56% 99.87% 99.23% 100.00% 54.30% 100.37%
Interest Burden Percent
169.75% 101.62% 99.70% 98.84% 95.92% 98.46% 94.74% 98.58% 232.34% 106.80%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-0.55% -66.22% -100.07% -92.37% -28.63% -112.63% -84.49% -121.01% -28.71% -138.22%
ROIC Less NNEP Spread (ROIC-NNEP)
0.22% -56.57% -90.36% -86.16% -25.53% -103.02% -79.86% -116.91% -24.97% -130.97%
Return on Net Nonoperating Assets (RNNOA)
-0.08% 23.02% 44.31% 52.71% 12.70% 54.14% 48.85% 88.91% 17.07% 95.24%
Return on Equity (ROE)
-0.63% -43.20% -55.77% -39.67% -15.93% -58.48% -35.64% -32.10% -11.64% -42.98%
Cash Return on Invested Capital (CROIC)
-78.04% -69.87% -78.42% -123.89% -143.90% -160.22% -162.05% -175.67% -163.70% -160.44%
Operating Return on Assets (OROA)
-0.77% -30.06% -39.99% -29.27% -9.93% -38.49% -25.44% -25.34% -6.65% -29.23%
Return on Assets (ROA)
-0.65% -30.49% -39.81% -29.13% -9.19% -37.85% -23.92% -24.98% -8.39% -31.34%
Return on Common Equity (ROCE)
-0.63% -43.20% -55.77% -39.66% -15.93% -58.48% -35.64% -32.09% -11.64% -42.98%
Return on Equity Simple (ROE_SIMPLE)
0.00% -58.65% -56.79% -43.32% 0.00% -34.57% -28.19% -29.97% 0.00% -72.38%
Net Operating Profit after Tax (NOPAT)
-0.14 -11 -15 -13 -4.75 -12 -9.14 -9.64 -2.45 -7.92
NOPAT Margin
-0.21% -23.50% -33.67% -25.98% -7.63% -30.60% -21.78% -22.85% -4.92% -23.97%
Net Nonoperating Expense Percent (NNEP)
-0.77% -9.65% -9.71% -6.21% -3.11% -9.60% -4.62% -4.10% -3.74% -7.26%
Return On Investment Capital (ROIC_SIMPLE)
-0.09% - - - -2.49% - - - -2.16% -
Cost of Revenue to Revenue
19.26% 19.86% 19.75% 19.81% 18.44% 19.62% 18.29% 19.05% 18.13% 18.42%
SG&A Expenses to Revenue
19.81% 30.00% 31.98% 28.10% 21.62% 31.13% 23.91% 25.75% 20.91% 26.97%
R&D to Revenue
7.58% 11.01% 11.60% 10.29% 6.67% 10.67% 8.40% 8.09% 7.53% 11.49%
Operating Expenses to Revenue
80.87% 113.66% 128.09% 117.15% 92.11% 124.04% 112.59% 113.60% 88.90% 115.82%
Earnings before Interest and Taxes (EBIT)
-0.60 -15 -21 -19 -6.78 -18 -13 -14 -3.50 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
1.49 -13 -19 -17 -5.31 -17 -12 -13 -2.63 -11
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
4.11 3.44 3.68 6.37 5.70 5.85 10.46 9.78 21.08 19.66
Price to Tangible Book Value (P/TBV)
5.04 4.31 4.54 7.68 6.77 6.97 12.29 9.78 21.08 19.66
Price to Revenue (P/Rev)
2.21 1.78 2.08 4.11 4.20 4.62 9.40 9.94 9.00 9.74
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
4.87 4.40 5.27 10.77 10.57 10.75 23.40 34.87 39.00 45.14
Enterprise Value to Revenue (EV/Rev)
2.11 1.63 1.87 3.82 3.83 4.22 8.88 9.18 8.79 9.46
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.47 0.51 0.47 0.42 0.38 0.38 0.35 0.33 0.87 0.85
Long-Term Debt to Equity
0.47 0.51 0.47 0.42 0.38 0.38 0.35 0.33 0.87 0.85
Financial Leverage
-0.37 -0.41 -0.49 -0.61 -0.50 -0.53 -0.61 -0.76 -0.68 -0.73
Leverage Ratio
1.87 1.87 1.82 1.73 2.07 1.98 1.84 1.62 1.95 1.84
Compound Leverage Factor
3.17 1.90 1.81 1.71 1.99 1.95 1.75 1.60 4.54 1.97
Debt to Total Capital
32.07% 33.66% 32.16% 29.58% 27.76% 27.74% 26.06% 25.09% 46.55% 45.84%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
32.07% 33.66% 32.16% 29.58% 27.76% 27.74% 26.06% 25.09% 46.55% 45.84%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
67.93% 66.34% 67.84% 70.42% 72.24% 72.26% 73.94% 74.88% 53.45% 54.16%
Debt to EBITDA
-1.11 -0.96 -0.91 -1.03 -1.12 -1.19 -1.36 -1.39 -1.60 -1.49
Net Debt to EBITDA
0.46 0.53 0.71 1.11 1.49 1.56 2.24 3.11 0.87 1.02
Long-Term Debt to EBITDA
-1.11 -0.96 -0.91 -1.03 -1.12 -1.19 -1.36 -1.39 -1.60 -1.49
Debt to NOPAT
-1.37 -1.22 -1.17 -1.34 -1.47 -1.57 -1.81 -1.86 -2.16 -2.04
Net Debt to NOPAT
0.57 0.68 0.92 1.44 1.95 2.05 2.97 4.16 1.17 1.39
Long-Term Debt to NOPAT
-1.37 -1.22 -1.17 -1.34 -1.47 -1.57 -1.81 -1.86 -2.16 -2.04
Altman Z-Score
3.10 2.15 2.34 4.52 4.78 5.23 10.13 10.95 8.62 8.44
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.04% 0.03% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
4.62 4.12 3.86 3.98 4.40 5.64 6.60 9.58 4.41 5.66
Quick Ratio
3.34 2.80 2.71 2.98 3.58 4.44 5.55 8.41 3.65 4.74
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-23 -17 -22 -42 -41 -55 -50 -33 -18 -17
Operating Cash Flow to CapEx
-136.86% -413.62% -803.76% -183.88% 23.67% -271.72% -197.00% -1,167.73% -229.76% -127.76%
Free Cash Flow to Firm to Interest Expense
-17.44 -13.18 -16.68 -31.85 -31.06 -42.29 -38.79 -25.44 -1.74 -14.27
Operating Cash Flow to Interest Expense
-3.20 -9.02 -10.59 -5.48 0.41 -7.34 -6.50 -13.43 -0.52 -6.29
Operating Cash Flow Less CapEx to Interest Expense
-5.54 -11.20 -11.91 -8.46 -1.32 -10.04 -9.80 -14.58 -0.75 -11.21
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.89 0.90 0.83 0.80 0.91 0.88 0.82 0.78 0.95 0.85
Accounts Receivable Turnover
5.31 8.25 7.52 7.07 5.56 8.02 7.64 7.49 5.94 8.27
Inventory Turnover
1.20 1.08 1.14 1.28 1.45 1.42 1.57 1.69 1.71 1.61
Fixed Asset Turnover
8.68 8.69 9.09 9.70 9.94 9.79 11.85 15.57 15.60 15.33
Accounts Payable Turnover
3.68 2.88 2.93 2.84 3.43 3.95 5.48 6.67 4.01 4.24
Days Sales Outstanding (DSO)
68.75 44.24 48.53 51.62 65.60 45.49 47.80 48.70 61.46 44.12
Days Inventory Outstanding (DIO)
304.22 338.37 320.44 285.87 251.98 257.06 232.49 215.80 213.66 226.42
Days Payable Outstanding (DPO)
99.29 126.81 124.69 128.42 106.36 92.33 66.58 54.70 90.95 86.10
Cash Conversion Cycle (CCC)
273.68 255.80 244.28 209.07 211.22 210.22 213.72 209.81 184.16 184.43
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
91 75 70 69 68 69 63 41 32 26
Invested Capital Turnover
2.65 2.82 2.97 3.56 3.75 3.68 3.88 5.29 5.84 5.77
Increase / (Decrease) in Invested Capital
23 6.71 6.91 29 36 42 41 23 15 9.06
Enterprise Value (EV)
441 331 370 748 716 738 1,482 1,423 1,247 1,187
Market Capitalization
463 361 412 805 786 807 1,569 1,541 1,276 1,223
Book Value per Share
$1.81 $1.69 $1.81 $2.05 $2.24 $2.24 $2.45 $2.58 $1.09 $1.12
Tangible Book Value per Share
$1.48 $1.35 $1.46 $1.70 $1.88 $1.88 $2.08 $2.58 $1.09 $1.12
Total Capital
166 158 165 179 191 191 203 210 113 115
Total Debt
53 53 53 53 53 53 53 53 53 53
Total Long-Term Debt
53 53 53 53 53 53 53 53 53 53
Net Debt
-22 -30 -42 -57 -70 -69 -87 -118 -29 -36
Capital Expenditures (CapEx)
3.07 2.86 1.73 3.93 2.25 3.50 4.23 1.48 2.33 5.86
Debt-free, Cash-free Net Working Capital (DFCFNWC)
51 37 32 30 30 32 29 29 22 17
Debt-free Net Working Capital (DFNWC)
126 119 127 140 153 154 168 200 103 105
Net Working Capital (NWC)
126 119 127 140 153 154 168 200 103 105
Net Nonoperating Expense (NNE)
0.36 4.77 6.24 5.40 1.53 5.05 3.13 3.81 1.96 4.21
Net Nonoperating Obligations (NNO)
-22 -30 -42 -57 -70 -69 -87 -117 -29 -36
Total Depreciation and Amortization (D&A)
2.09 2.00 1.84 1.65 1.47 1.27 0.80 0.70 0.87 0.53
Debt-free, Cash-free Net Working Capital to Revenue
24.26% 18.01% 16.15% 15.48% 16.10% 18.22% 17.13% 18.82% 15.44% 13.37%
Debt-free Net Working Capital to Revenue
60.41% 58.83% 64.02% 71.59% 81.94% 88.16% 100.66% 128.94% 72.73% 83.92%
Net Working Capital to Revenue
60.41% 58.83% 64.02% 71.59% 81.94% 88.16% 100.66% 128.94% 72.73% 83.92%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.01) ($0.25) ($0.34) ($0.30) ($0.10) ($0.28) ($0.20) ($0.23) ($0.08) ($0.22)
Adjusted Weighted Average Basic Shares Outstanding
62.11M 62.23M 62.08M 61.79M 60.85M 61.56M 61.38M 58.72M 55.28M 55.43M
Adjusted Diluted Earnings per Share
($0.01) ($0.25) ($0.34) ($0.30) ($0.10) ($0.28) ($0.20) ($0.23) ($0.08) ($0.22)
Adjusted Weighted Average Diluted Shares Outstanding
62.11M 62.23M 62.08M 61.79M 60.85M 61.56M 61.38M 58.72M 55.28M 55.43M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
62.62M 62.30M 62.19M 62.01M 61.76M 61.68M 61.54M 61.33M 61.16M 55.50M
Normalized Net Operating Profit after Tax (NOPAT)
-0.14 -11 -15 -13 -4.75 -12 -9.14 -9.64 -2.45 -7.92
Normalized NOPAT Margin
-0.21% -23.50% -33.67% -25.98% -7.63% -30.60% -21.78% -22.85% -4.92% -23.97%
Pre Tax Income Margin
-1.47% -34.13% -47.77% -36.30% -10.46% -43.04% -29.48% -31.89% -16.33% -36.57%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-0.45 -11.53 -16.24 -14.25 -5.20 -13.75 -10.18 -10.62 -0.34 -9.51
NOPAT to Interest Expense
-0.11 -8.07 -11.41 -10.08 -3.64 -9.62 -7.13 -7.50 -0.24 -6.66
EBIT Less CapEx to Interest Expense
-2.79 -13.71 -17.55 -17.23 -6.92 -16.45 -13.48 -11.77 -0.57 -14.43
NOPAT Less CapEx to Interest Expense
-2.45 -10.25 -12.73 -13.06 -5.36 -12.33 -10.43 -8.65 -0.47 -11.58
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Treace Medical Concepts' Financials

When does Treace Medical Concepts's financial year end?

According to the most recent income statement we have on file, Treace Medical Concepts' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Treace Medical Concepts' net income changed over the last 2 years?

Treace Medical Concepts' net income appears to be on an upward trend, with a most recent value of -$55.74 million in 2024, rising from -$42.82 million in 2022. The previous period was -$49.53 million in 2023. See where experts think Treace Medical Concepts is headed by visiting Treace Medical Concepts' forecast page.

What is Treace Medical Concepts's operating income?
Treace Medical Concepts's total operating income in 2024 was -$55.69 million, based on the following breakdown:
  • Total Gross Profit: $168.26 million
  • Total Operating Expenses: $223.63 million
How has Treace Medical Concepts revenue changed over the last 2 years?

Over the last 2 years, Treace Medical Concepts' total revenue changed from $141.84 million in 2022 to $209.36 million in 2024, a change of 47.6%.

How much debt does Treace Medical Concepts have?

Treace Medical Concepts' total liabilities were at $104.20 million at the end of 2024, a 8.6% decrease from 2023, and a 5.8% increase since 2022.

How much cash does Treace Medical Concepts have?

In the past 2 years, Treace Medical Concepts' cash and equivalents has ranged from $11.35 million in 2024 to $19.47 million in 2022, and is currently $11.35 million as of their latest financial filing in 2024.

How has Treace Medical Concepts' book value per share changed over the last 2 years?

Over the last 2 years, Treace Medical Concepts' book value per share changed from 1.09 in 2022 to 1.81 in 2024, a change of 66.2%.



This page (NASDAQ:TMCI) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners